Patterns and factors associated with low adherence to psychotropic medications during pregnancy-a cross-sectional, multinational webbased study.

Lupattelli A,¹ Spigset O,^{2,3} Björnsdóttir I,¹ Hameen-Anttila K,⁴ Mårdby AC,⁵ Panchaud A,⁶ Gjergja Juraski R,⁷ Rudolf G,⁸ Odalovic M,⁹ Drozd M,¹⁰ Twigg MJ,¹¹ Juch H,¹² Moretti ME,¹³ Kennedy D,¹⁴ Rieutord A,¹⁵ Zagorodnikova K,¹⁶ Passier JLM,¹⁷ Nordeng H^{1,18}.

Abstract

Background: No previous studies have explored how closely women follow their psychotropic drug regimens during pregnancy. This study aimed to explore patterns of and factors associated with low adherence to psychotropic medication during pregnancy. **Methods:** Multinational web-based study was performed in 18 countries in Europe, North America, and Australia. Uniform data collection was ensured via an electronic questionnaire. Pregnant women were eligible to participate. Adherence was measured via the 8-item Morisky Medication Adherence Scale (MMAS-8). The Beliefs about Prescribed Medicines Questionnaire (BMQ-specific), the Edinburgh Postnatal Depression Scale (EPDS), and a numeric rating scale were utilized to measure women's beliefs, depressive symptoms, and antidepressant risk perception, respectively. Participants reporting use of psychotropic medication during pregnancy (n = 160) were included in the analysis.

Results: On the basis of the MMAS-8, 78 of 160 women (48.8%, 95% CI: 41.1-56.4%) demonstrated low adherence during pregnancy. The rates of low adherence were 51.3% for medication for anxiety, 47.2% for depression, and 42.9% for other psychiatric disorders. Smoking during pregnancy, elevated antidepressant risk perception (risk≥6), and depressive symptoms were associated with a significant 3.9-, 2.3-, and 2.5-fold increased likelihood of low medication adherence, respectively. Women on psychotropic polytherapy were less likely to demonstrate low adherence. The belief that the benefit of pharmacotherapy outweighed the risks positively correlated (r = .282) with higher medication adherence.

¹School of Pharmacy, University of Oslo, Norway

²Department of Clinical Pharmacology, St Olav's University Hospital, Trondheim, Norway ³Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway

⁴Finnish Medicines Agency, Kuopio, Finland

⁵Department of Public Health and Community Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

⁶School of Pharmaceutical Sciences, University of Geneva and Lausanne, Geneva, Switzerland

⁷Children's Hospital Srebrnjak, Neuropediatric Unit, Zagreb, Croatia

⁸Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Slovenia

⁹Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of Pharmacy, University of Belgrade, Serbia

¹⁰Faculty of Pharmacy, Medical University of Lublin, Poland

¹¹School of Pharmacy, University of East Anglia, Norwich Research Park, United Kingdom ¹²Research Unit Human Teratogens, Institute for Cell Biology, Histology and Embryology,

Medical University of Graz, Austria

13 The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, Ontario, Canada

¹⁴MotherSafe, Royal Hospital for Women and University of NSW, Randwick, Australia ¹⁵APHP, GH HUPS, Hop Antoine Béclère, Service Pharmacie, Clamart France and Européenne de Formation pour les Pharmaciens, France

¹⁶Northwest Medical Center for Drug Safety in Pregnancy & Lactation, Northwest State Medical University n.a.I.I.Mechnikov, St. Petersburg, Russia

Conclusions: Approximately one of two pregnant women using psychotropic medication demonstrated low adherence in pregnancy. Life-style factors, risk perception, depressive symptoms, and individual beliefs are important factors related to adherence to psychotropic medication in pregnancy.

Published in: Depression and Anxiety 2015 doi: 10.1002/da.22352.

Contact: Alice.Panchaud@chuv.ch